Ascentage Pharma - AAPG Enterprise Value-to-Revenue Multiple

Public company logo of ascentage.com (AAPG)

Can the demand for resistant tumor therapies drive growth for Ascentage Pharma Group (AAPG)? Success depends on Olverembatinib sales, regulatory approvals, and liquidity. Business stability relies on late-stage developments in the US and China. A business valuation via EV/Sales visualizes the asset's dynamics, where the value 12973.75 captures the metric level.

AAPG: Ascentage Pharma Group International Company Value to Revenue 11/23/2025 - 11/20/2026

Ascentage Pharma Group International - analytical breakdowns and key metrics (AAPG)

Fundamental company valuation:AAPG, Ascentage Pharma
Mass-produced product of Ascentage Pharma

An analysis of the EV-to-total-revenue multiple confirms the status of Ascentage Pharma Group (AAPG) as a non-cyclical oncology drug developer whose valuation is independent of seasonality. This indicator compares the total enterprise value of the business with annual turnover, excluding net debt, allowing investors to assess the real price of assets amid tight Fed policy and high market sensitivity to interest rates.

Direct competitors

Enterprise Value-to-Sales Ratio BeiGene Ltd (ONC)|Halozyme Corp (HALO) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple Revolution Medicines Inc (RVMD)|Enterprise Value-to-Revenue Ratio CG Oncology, Inc.|Enterprise Value-to-Revenue Multiple UroGen Pharma Corp URGN|EV/Sales Multiple BCAX|Personalis, Inc. - Company Value to Revenue Ratio|Erasca - Company Value to Revenue|Business Value to Revenue DCTH|YMAB: Company Value to Revenue|Enterprise Value-to-Revenue Multiple Aura Corp|CADL: EV/Sales Multiple|ARAY - Total Company Value-to-Revenue Ratio|SLS (SELLAS Life Sciences Group, Inc.) - EV/Sales Multiple|ACTU: Business Value to Revenue|Enterprise Value-to-Revenue Ratio citiusonc.com (CTOR)|Total Company Value-to-Revenue Ratio TuHURA Biosciences|Enterprise Value-to-Revenue Ratio Protara Therapeutics TARA|Fate Therapeutics (FATE) - Enterprise Value-to-Revenue Multiple|WHWK - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Multiple TScan Therapeutics Inc|championsoncology.com (CSBR) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Ratio XBIT|Company Value to Revenue CVM|Company Value to Revenue Ratio OSTX (OS Therapies Incorporated)|EV/Sales Multiple RADX|ARTV: Enterprise Value to Sales Volume|EV/Sales Multiple ANL (Adlai Nortye Ltd)|VERU - Company Value to Revenue|tempesttx.com - EV/Sales Multiple|Business Value to Revenue XLO (xiliotx.com)|RENB: EV/Sales Multiple|Company Value to Revenue Mural Oncology plc|Enterprise Value-to-Revenue Ratio Kairos Pharma Inc|OKUR: Business Value to Revenue|EV/Sales Multiple GDTC|CRIS (Curis) - Business Value to Revenue|Enterprise Value-to-Revenue Ratio apollomicsinc.com APLM|THAR: Company Value to Revenue Ratio|advanbiomed.com - EV/Sales Multiple|Business Value to Revenue GNPX (Genprex, Inc)|Calidi Biotherapeutics Inc. (CLDI) - Enterprise Value-to-Revenue Ratio|Sunshine Biopharma Inc. (SBFM) - EV/Sales Multiple|XBIO (Xenetic Bio) - EV/Sales Multiple|Salarius Pharmaceuticals Inc (SLRX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PPBT|EV/Sales Multiple American Oncology Network Inc (AONC)|EV/Sales Multiple BGNE (BeiGene Ltd.)|Enterprise Value-to-Revenue Coefficient CKPT (Checkpoint Therapeutics)|ELEV - Enterprise Value-to-Revenue Ratio|ICAD (iCAD Inc.) - Company Value to Revenue Ratio|Ikena (IKNA) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Notable Labs, Ltd.|Enterprise Value-to-Revenue Ratio viracta.com|MOR: Business Value to Revenue|EV/Sales Multiple NAYA|Ascentage Pharma - Company Value to Revenue Ratio